WhiteSwell Medical News
5 articlesWhiteSwell Adds Experienced Executives to its Senior Management Team
growth-positive
Catheter Stimulates Lymphatic Drainage for Heart Failure Treatment: Interview with Eamon Brady, CEO of WhiteSwell
WhiteSwell, a medtech company based in Galway, Ireland, has developed a catheter system to treat acute decompensated heart failure (ADHF). The technology stimulates lymphatic drainage to aid with decongestion without the need for diuretics. The company recently announced a US patent for the device and has conducted early feasibility studies in humans. ADHF affects millions of people globally and contributes to millions of hospitalizations each year. WhiteSwells technology has the potential to completely and rapidly decongest ADHF patients and protect kidney function. The company plans to continue clinical evaluation and move forward with extensive clinical trials.
Customers
WhiteSwell Strengthens Patent Portfolio for Treatment of Acute Decompensated Heart Failure With Newly Issued U.S. Patent
Growth-Positive
Europe Start-up 100: 25 medtech and life sciences start-ups to watch in 2019
The article lists 25 European medtech and life sciences start-ups to watch in 2019. These start-ups are pushing the innovation envelope further than ever thought possible. The start-ups listed are Ada, Aiforia, Ava, Bambi Medical, BioBeats, BrainWaveBank, Diaceutics, Dobco Medical Systems, Doctena, Etsimo, Fluidic Analytics, HealthBeacon, Heartbeat Medical, Healthera, Healx, Kite Medical, Medherant, Neurent Medical, Nuritas, Oura, Sword Health, UgenTec, Ultromics, WhiteSwell, and Xeltis.
CustomersInvestmentPartners
growth-positive
Israeli Medical Device Company WhiteSwell Raises $30 Million
WhiteSwell Ltd., a medical device company based in Ireland, has raised $30 million in a series B funding round led by RA Capital Management and InCube Ventures. The company plans to use the funding to develop its catheter-based technology for the treatment of acute decompensated heart failure (ADHF), a condition that causes severe fluid buildup in multiple organs. ADHF is responsible for nearly two million hospitalizations per year in the U.S. WhiteSwell is currently conducting an early feasibility study for the treatment at clinical sites in the U.S., Israel, and Europe.
Investment
